Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation: All‐cause mortality
Double‐dose adenovirus‐thymidine kinase with ganciclovir… may leads to lower all‐cause mortality compared with liver transplantation (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation All‐cause mortality · participants with unresectable hepatocellular carcinoma Double‐dose adenovirus‐thymidine kinase with ganciclovir… may leads to lower all‐cause mortality compared with liver transplantation (low certainty). Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane Headline outcomes only | RR 0.4 [0.22, 0.73] | 1 study · 86 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.